At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 125 enrolled
Drug / intervention
RO7490677 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)
In Brief
A Phase 2 clinical trial evaluating RO7490677 and Ruxolitinib for Primary Myelofibrosis and 2 related conditions. Completed, enrolled 125 participants across 23 sites in 8 countries.
Detailed Summary
RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue. The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, France, Germany, Israel, Italy, Netherlands, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedNov 2013
Primary CompletionJul 2020
TodayJul 2026
First PostedNov 13, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 10, 2020
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 12.6 years ago
Interventions
RO7490677biological
IV infusion
Ruxolitinibdrug
IV infusion